{"id":"aflibercept-intravitreous-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human immunoglobulin G. By sequestering VEGF-A, VEGF-B, and PlGF in the vitreous, it inhibits pathological neovascularization and vascular permeability that characterize retinal diseases. This mechanism reduces fluid accumulation and abnormal vessel formation in conditions like wet age-related macular degeneration and diabetic macular edema.","oneSentence":"Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial cell receptors and reducing abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:56.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (AMD)"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Myopic choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT07365371","phase":"PHASE4","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-01","conditions":"Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)","enrollment":174},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT01940887","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-05","conditions":"Age-Related Macular Degeneration","enrollment":645},{"nctId":"NCT03321513","phase":"PHASE3","title":"DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2017-12-07","conditions":"Diabetic Macular Edema","enrollment":270},{"nctId":"NCT02634333","phase":"PHASE3","title":"Anti-VEGF Treatment for Prevention of PDR/DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":399},{"nctId":"NCT02858076","phase":"PHASE2, PHASE3","title":"Anti-VEGF vs. Prompt Vitrectomy for VH From PDR","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-11","conditions":"Proliferative Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":205},{"nctId":"NCT04707027","phase":"NA","title":"Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-11-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":80},{"nctId":"NCT03920878","phase":"PHASE2","title":"Cataract DME - Peri vs. Intraop","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2020-05","conditions":"Diabetic Macular Edema, Cataract","enrollment":""},{"nctId":"NCT02860858","phase":"PHASE4","title":"Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2016-12-30","conditions":"Symtomatic Macular Polypoidal Choroidal Vasculopathy","enrollment":50},{"nctId":"NCT02457975","phase":"EARLY_PHASE1","title":"Photobiomodulation for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-06","conditions":"Diabetic Retinopathy","enrollment":16},{"nctId":"NCT02441816","phase":"PHASE4","title":"VITAL - Individualising Therapy for Neovascular AMD With Aflibercept","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2014-11","conditions":"Age Related Macular Degeneration","enrollment":50},{"nctId":"NCT02645734","phase":"PHASE2, PHASE3","title":"The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"","conditions":"Diabetic Macular Edema","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aflibercept Intravitreous Injection","genericName":"Aflibercept Intravitreous Injection","companyName":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-general-hospital-shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endothelial cell receptors and reducing abnormal blood vessel growth in the eye. Used for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}